410 related articles for article (PubMed ID: 24469108)
1. CD74-NRG1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
[TBL] [Abstract][Full Text] [Related]
2. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.
Gow CH; Wu SG; Chang YL; Shih JY
Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract][Full Text] [Related]
5. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
6. NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.
Duruisseaux M; McLeer-Florin A; Antoine M; Alavizadeh S; Poulot V; Lacave R; Rabbe N; Cadranel J; Wislez M
Cancer Med; 2016 Dec; 5(12):3579-3585. PubMed ID: 27770508
[TBL] [Abstract][Full Text] [Related]
7. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
Werr L; Plenker D; Dammert MA; Lorenz C; Brägelmann J; Tumbrink HL; Klein S; Schmitt A; Büttner R; Persigehl T; Shokat KM; Wunderlich FT; Schram AM; Peifer M; Sos ML; Reinhardt HC; Thomas RK
Mol Cancer Ther; 2022 May; 21(5):821-830. PubMed ID: 35247925
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.
Fernandez-Cuesta L; Thomas RK
Clin Cancer Res; 2015 May; 21(9):1989-94. PubMed ID: 25501131
[TBL] [Abstract][Full Text] [Related]
9. VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.
Jung Y; Yong S; Kim P; Lee HY; Jung Y; Keum J; Lee S; Kim J; Kim J
J Thorac Oncol; 2015 Jul; 10(7):1107-11. PubMed ID: 26134228
[TBL] [Abstract][Full Text] [Related]
10. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.
Murayama T; Nakaoku T; Enari M; Nishimura T; Tominaga K; Nakata A; Tojo A; Sugano S; Kohno T; Gotoh N
Cancer Res; 2016 Feb; 76(4):974-83. PubMed ID: 26837769
[TBL] [Abstract][Full Text] [Related]
12. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
13. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
Nakaoku T; Tsuta K; Ichikawa H; Shiraishi K; Sakamoto H; Enari M; Furuta K; Shimada Y; Ogiwara H; Watanabe S; Nokihara H; Yasuda K; Hiramoto M; Nammo T; Ishigame T; Schetter AJ; Okayama H; Harris CC; Kim YH; Mishima M; Yokota J; Yoshida T; Kohno T
Clin Cancer Res; 2014 Jun; 20(12):3087-93. PubMed ID: 24727320
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.
Jun HJ; Johnson H; Bronson RT; de Feraudy S; White F; Charest A
Cancer Res; 2012 Aug; 72(15):3764-74. PubMed ID: 22659450
[TBL] [Abstract][Full Text] [Related]
15. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
16. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Characteristics of NRG1 Fusion-Positive Solid Tumors in Korean Patients.
Cha YJ; Lee C; Joo B; Kim KA; Lee CK; Shim HS
Cancer Res Treat; 2023 Oct; 55(4):1087-1095. PubMed ID: 37321274
[TBL] [Abstract][Full Text] [Related]
18. Frequent
Trombetta D; Graziano P; Scarpa A; Sparaneo A; Rossi G; Rossi A; Di Maio M; Antonello D; Mafficini A; Fabrizio FP; Manzorra MC; Balsamo T; Centra F; Simbolo M; Pantalone A; Notarangelo M; Parente P; Lucia Dimitri MC; Bonfitto A; Fiordelisi F; Storlazzi CT; L'Abbate A; Taurchini M; Maiello E; Fazio VM; Muscarella LA
Oncotarget; 2018 Feb; 9(11):9661-9671. PubMed ID: 29515761
[No Abstract] [Full Text] [Related]
19. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.
Dhanasekaran SM; Balbin OA; Chen G; Nadal E; Kalyana-Sundaram S; Pan J; Veeneman B; Cao X; Malik R; Vats P; Wang R; Huang S; Zhong J; Jing X; Iyer M; Wu YM; Harms PW; Lin J; Reddy R; Brennan C; Palanisamy N; Chang AC; Truini A; Truini M; Robinson DR; Beer DG; Chinnaiyan AM
Nat Commun; 2014 Dec; 5():5893. PubMed ID: 25531467
[TBL] [Abstract][Full Text] [Related]
20. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]